Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. The company was founded in 1995 and is headquartered in Melbourne, Australia.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [10/18/2019 07:51 PDT] BNTC Expected to Trade Up After Bullish Patterns Develop
• [09/20/2019 12:23 PDT] Benitec Biopharma Limited (NASDAQ:BNTC), Up By 100.00% ($0.69) From $0.690 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [09/20/2019 06:59 PDT] BNTC Expected to Trade Up After Bullish Patterns Develop
• [09/17/2019 11:07 PDT] Benitec Biopharma Limited (NASDAQ:BNTC), Up By 100.00% ($0.71) From $0.714 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [09/04/2019 07:47 PDT] BNTC Expected to Trade Up After Bullish Patterns Develop